

Kære Pia,

Tak fordi du engagerer dig - det er det politik handler om.

T. Gondii problemet er reelt og virkeligt - også selv om det kan fremprovokere lidt frygt i de fleste.

Vi (som er et uformelt internationalt research kollektiv) har arbejdet meget intensivt med sagen i lang tid og har løbende informeret myndighederne, patientforeningerne og industrien i takt med at billedet foldede sig ud.

Vores oprindelige vinkel var Diabetes (som der er særdeles god grund til at antage at TG er væsentlig faktor i) men vi indså ret tidligt i processen at TG er et problem som er større og noget som ingen havde set før.

Vi opdagede også, at hvis man er inficeret er denne sag meget svær at tilnærme sig intellektuelt, i det T. Gondii - lidt populært sagt - ikke er meget for at blive opdaget.

Personligt har jeg arbejdet næsten fuld tid med sagen i over et år og startede med at informere myndighederne i Danmark i februar (Sundhedsministeriet, Statens Serum Institut og Sundhedsstyrelsen mv.).

Al information er også tilsendt Folketingets Sundhedsudvalg og er nu "on record" i Folketinget.

Vi har naturligvis også informeret medicinal industrien - se venligst nedenfor seneste herom til orientering.

Som det fremgår er der en meget lang række måder at løse problemet på - og mange af dem er nemme, billige og tilgængelige.

Med venlig hilsen
Bo Hembæk Svensson

----- Forwarded message -----

From: **Bo Svensson** <cooldane@gmail.com>

Date: Tue, Sep 23, 2014 at 11:24 AM

Subject: New evidence support causality between T. Gondii and Diabetes, Schizophrenia, Alzheimers/Parkinson etc

To: lrs@novonordisk.com, mkt@novonordisk.com, investor@lundbeck.com

Cc: Henrik Nedergaard <HN@diabetes.dk>, Nis Peter Nissen <Nis@alzheimer.dk>, Bente Friborg <bentefriborg@gmail.com>

To: The Management of Novo Nordisk and Lundbeck

Dear Sirs,

We have consistently been alerting you to the fact that a significant number of scientists, doctors and scholars is warning us about T. Gondii's *devastating* effect on humans.

We have also conveyed facts and documentation that places the phenomenon of T. Gondii as part of a bigger picture.

We have conveyed several scientific papers suggesting a direct causal connection between diabetes and T. Gondii infections and an even greater number of papers suggesting causality related to Alzheimer, Schizophrenia, Parkinson, Depression, Obesity, various forms of cancer and so forth.

Several science teams describes T. Gondii as a "Global Threat", and authorities from UN, US, Iceland, Sweden, Holland and others have recently issued warnings and has been alerting policy makers and the health-care sector.

Recently Professor Rima McLoud and her team of scientists from USA, France, England and Canada stepped out and informed us about their findings - directly warning against "*the devastating diseases this parasite causes.*"

From the work of Professor McLoud (<http://sciencelife.uchospitals.edu/2014/07/22/what-does-it-mean-when-2-billion-people-share-their-brain-with-a-parasite/>) we learn that an even newer connection has been made, that gives deep meaning and correlates perfectly to what we have learnt so far concerning T. Gondii and its causality:

"We just published a paper on **ALOX12** in the journal Infection and Immunity. We are early in the process of studying all the genes, but the results so far are fascinating. We have used a candidate gene approach. The first two genes we examined, one from either end of Toxo1 region, had variations that correlate at a high level with either susceptibility or resistance. Earlier, we had found this in the gene at the bottom of the region, known as caterpillar at the time. In this current paper, we found it in a gene at the top of the region, called ALOX12. This is a cell-death gene. Technically, it is a lipoxygenase that adds a toxic, unstable oxygen to the 12th carbon of arachidonic acid—creating a biologically harmful molecule. **Others had found evidence of ALOX12 influencing outcomes in diabetes, neurodegenerative disease and schizophrenia, but there was nothing known about its role in infectious diseases.**

"When we reduced ALOX12, the inflammatory and cell-death activities that protect against toxoplasmosis decreased. It became likely that certain variants of this gene were more effective than others at triggering inflammation and killing infected and nearby cells and parasites (...) Without the product of this gene the same cells were unable to constrain the infection. When we tested these cells with the ALOX12 gene rendered inactive, the parasites proliferated rapidly."

We also learn that:

"Toxoplasma infects nerve cells. Certain versions of ALOX12 and NALP1 can help an infected person mount a strong, early, protective, immune response, killing parasites, infected cells as well as nearby cells. But we also know that ALOX12 is **associated with diseases related to aging and memory loss**. When we utilized our findings about ALOX12 with systems-biology programs, used to map out pathways, we realized that many of these pathways were also in play in various

neurodegenerative diseases, such as **Alzheimer's** and even **schizophrenia**. Some may contribute to **atherosclerosis** or **diabetes**. When this powerful immune response remains on the job it can have effects that might be harmful."

(...) More effective medicines or a vaccine could protect against the devastating diseases this parasite causes."

On behalf of the 1.5 million infected in Denmark we ask you:

How much more evidence does the pharmaceutical industry need to engage ?

How many lives should be devastated by *Toxoplasma Gondii* before we all step in and solve the problem ?

Especially Novo Nordisk and Lundbeck plays a crucial role in solving this problem that is *recognized, documented and has a very strong scientific chain-of-argument*

For the last year we have been collecting information concerning how to deal with *Toxoplasma Gondii* - and we have a long list of remedies from pharmaceuticals and natural remedies to sound/frequency and nano-tech.

The list of *proven* remedies are surprisingly long - so we actually already have a host of options and tools to use to solve this problem all we need is to get the *process* started.

As you might be aware of we have been activating the danish (and foreign) authorities, and we start seeing the effect of this. The process has been very slow, but we now have traction at the political level in Denmark .

It is safe to say that we have not been confronted with a problem like this before and therefore only cooperation and out-of-the-box thinking will bring us towards a solution.

We will convey all of our findings, insights, documentation and so forth to anyone wishing to participate in addressing the issue.

Sincerely yours

Bo Hembæk Svensson et al.